2022 PADN-CFDA TRIAL Pulmonary artery denervation for pulmonary arterial hypertension (PAH) multicenter, sham-controlled single-blind, randomized controlled trial Objective: To evaluate the treatment effects of pulmonary artery denervation (PADN) among patients with Group I PAH who were not on PAH-specific drugs … Read More
